Canaccord Genuity Group (TSE:CF – Free Report) had its price target raised by TD Securities from C$10.00 to C$12.00 in a ...

On Wednesday, Blend Labs Inc (BLND) stock saw a decline, ending the day at $4.36 which represents a decrease of $-0.19 or -4.18% from the prior close of $4.55. The stock opened at $4.59 and touched a ...

Exchange Income (TSE:EIF – Free Report) had its price target upped by Canaccord Genuity Group from C$70.00 to C$72.00 in a ...

Fintel reports that on November 13, 2024, Canaccord Genuity downgraded their outlook for Doximity (NYSE:DOCS) from Buy to ...

Fintel reports that on November 13, 2024, Canaccord Genuity upgraded their outlook for Viant Technology (NasdaqGS:DSP) from ...

Canaccord Genuity on Wednesday downgraded Doximity (NYSE:DOCS) to hold from buy, noting that its shares, after a more than 30% rally following the company’s Q2 results, already reflect high ...

Canaccord Genuity Group Inc. recorded strong growth in wealth-management and capital-markets divisions for its fiscal second ...

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...

Firm-wide Revenue: $128 million for the quarter, up 27% year-over-year. Fiscal Year-to-Date Revenue: $857 million, up 26% ...

Good morning, ladies and gentlemen. Thank you for standing by. I'd like to welcome everyone to the Canaccord Genuity Group Inc. Fiscal 2025 Second Quarter Results Conference Call. All lines have been ...

Canaccord Genuity Group Inc (TSX:CF) is set to release its Q2 2025 earnings on Nov 7, 2024. The consensus estimate for Q2 2025 revenue is $0.43 million, and the earnings are expected to come in at $0.

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...